Navigation Links
Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy
Date:8/19/2010

ioembolisation plus 5FU (hazard ratio 0.38; p=0.003). The time to progression of disease anywhere in the body was also significantly longer, from a median of 2.1 months in the 5FU control arm to 4.5 months in patients in the radioembolisation/5FU arm (hazard ratio 0.51; p=0.03). Control of liver metastases was also significantly increased in patients receiving radioembolisation plus 5FU, from 35% to 85% (p=0.001). More patients in the 5FU-only control arm experienced severe side effects than those receiving radioembolisation plus 5FU (26% versus 5%; p=0.10).

The ability to show a difference in the overall survival of patients was blunted by the ethical design of the study, since patients receiving 5FU alone were reassessed once their cancer progressed, and, if possible, were treated with radioembolisation alone. Ten patients in the control arm later received radioembolisation and 6 received further chemotherapy, as did 9 patients in the radioembolisation plus 5FU group. Median overall survival was 7.3 months in the patients receiving 5FU alone, compared to 10.0 months in patients receiving radioembolisation plus 5FU, a difference that was not statistically significant.

"The combination of radioembolisation using 90Y-resin microspheres and 5FU chemotherapy was well tolerated and significantly improves the outcomes for patients compared with 5FU alone," said Dr Alain Hendlisz, chief of the gastroenterology unit at Institut Jules Bordet in Brussels, Belgium, and lead investigator of the trial. "The results of this randomised controlled trial provide Level 1 evidence that radioembolisation with 90Y-resin microspheres is a valid therapeutic option for patients with colorectal cancer liver metastases that have failed chemotherapy."

Large international randomised controlled trials are currently evaluating the effectiveness of radioembolisation using 90Y-resin microspheres with first-line chemotherapy in the treatment of patients with colorectal canc
'/>"/>

SOURCE Sirtex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
2. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
3. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
4. New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Fulton Project Advances to Phase 2 of Loan Guarantee Process
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
10. PRA International Opens Phase I Unit in Budapest
11. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Fleur’s introduces CC ... the benefits of makeup, skin care and solar ... cream is designed with specific complexion-correcting pigments to ... complexion and a healthy glow. Far more than ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Sterlitech ... ultrafiltration membranes, the PX, PY, and PZ ... sheets, and disks. Designed to be ideal ... new membranes can fill critical process requirements where ... downstream processes. , “New regulations on industrial wastewater ...
(Date:4/29/2015)... , April 29, 2015   Doximity , ... of all US doctors as members, announced a new, ... — "Apply Using Doximity." With one click, all US ... a curriculum vitae (CV) for an open job opportunity, ... directly. Eighty seven percent of physicians are ...
(Date:4/29/2015)... NY (PRWEB) April 29, 2015 Gene therapy ... replace it with the normal gene in human cardiac cells, ... Research Center at Icahn School of Medicine at Mount Sinai. ... Nature Communications. , “Genetic mutations, the small random, changes ... in the weakening heart muscle seen in patients with heart ...
Breaking Biology Technology:Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2Gene Therapy Clips Out Heart Failure Causing Gene Mutations 2Gene Therapy Clips Out Heart Failure Causing Gene Mutations 3Gene Therapy Clips Out Heart Failure Causing Gene Mutations 4
... Va., Aug. 20 Evolvent Technologies, Inc. (Evolvent), a ... government, announced today that it was awarded a contract ... for enhancements to the Bidirectional Health Information Exchange (BHIE) ... DoD information on a shared patient population. , ...
... researchers have incorporated inorganic nanoparticles that join with ... structures that have unusual optical and mechanical properties. ... growth and assembly processes of natural materials, taking ... reduce metal ions to produce nanoparticles without harsh ...
... MOUNTAIN VIEW, Calif., Aug. 19 Los ... innovator of cavity-enhanced laser-based instrumentation for analyses of gases and liquids, ... p e Analyzer (LWIA). "Our new ... of oxygen and hydrogen in liquid water on the market today," ...
Cached Biology Technology:Evolvent Awarded Health Information Exchange Contract 2Bio-enabled, surface-mediated approach produces nanoparticle composites 2Bio-enabled, surface-mediated approach produces nanoparticle composites 3Los Gatos Research Introduces Second Generation Liquid-Water Isotope Analyzer 2
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
(Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... , From neurosurgery to bar code readers, lasers have been ... introduced in the late 1950,s. Now, with the work being ... developed a way to use lasers to study the splicing ... to sustain advanced organisms, including human life. This process of ...
... study led by a University of Florida researcher uses tracking ... some of the fish swim directly to targeted locations. ... orient at large distances, with tiger sharks swimming in direct ... areas about 30 miles away, said lead author Yannis Papastamatiou, ...
... been selected as one of seven recipients to share ... to promote preventive care and reduce health care disparities ... its Centering Pregnancy program to address perinatal health care ... bring pregnant women with similar backgrounds together for group ...
Cached Biology News:Brandeis researchers use lasers, custom microscope to show gene splicing process in real time 2Brandeis researchers use lasers, custom microscope to show gene splicing process in real time 3New UF study shows some sharks follow 'mental map' to navigate seas 2New UF study shows some sharks follow 'mental map' to navigate seas 3Boston Medical Center to receive $245,000 grant from Attorney General Martha Coakley 2
... Clone/PAD: ZMD.283. Immunogen: Fusion ... Specificity: Specific for ASIP/PAR-3 (atypical PKC ... This antigen is not related to ... Reactivity: Human Dog Xenopus (positive controls: ...
...
Request Info...
normal rat IgM AF647...
Biology Products: